The University of New Mexico

fasd_image

NMARC Seminars

NMARC Seminars – Fall 2023 
“Treatments for Fetal Alcohol Spectrum Disorders” 
Jennifer Thomas, Ph.D., Department of Psychology, San Diego State University 
Thursday October 26, 2023 

“Behavioral interventions to mitigate the effects of developmental alcohol exposure on brain grey and white matter” 
Anna Klintsova, Ph.D., Department of Psychology, University of Delaware 
Thursday November 16 2023 

 

New Mexico Alcohol Research Center


1 University of New Mexico
Albuquerque, NM 87131

Welcome to the New Mexico Alcohol Research Center (NMARC)

Photo: Daniel SavageNMARC is a NIH NIAAA-designated, specialized Alcohol Research Center located at the University of New Mexico Health Sciences Center.  NMARC is one of just eighteen Alcohol Research Centers in the United States, and the only such center focused on Fetal Alcohol Spectrum Disorders (FASD).

FASD is a neurodevelopmental disorder estimated to affect between 2 and 5 percent of all children born in the United States.  The severity of FASD depends on the quantity, frequency and timing of drinking during pregnancy in conjunction with the occurrence of other risk factors associated with pregnancy.  The symptoms of FASD can range from subtle patterns of behavioral problems to more adverse behavioral outcomes coupled with altered physical features, referred to as Fetal Alcohol Syndrome (FAS). 

NMARC’s central focus is on understanding the neurobiological mechanisms underlying the behavioral problems associated with FASD, and to use this knowledge to help develop better methods of early diagnoses and more effective interventions for patients with FASD.

NMARC’s prevailing philosophy is that a research center organized to maximize the coordination, communication and synergistic integration across multiple lines of preclinical and clinical investigation provides the best long-term prospect of achieving significant progress towards the dual clinical goals of better diagnosis and more effective interventions for patients with FASD.